Key clinical point:
Major finding: After 24 weeks, the endoscopic nasal polyp score averaged a clinically meaningful 2.06 points lower on dupilumab, compared with placebo.
Study details: SINUS-24, a multicenter randomized trial with 276 patients.
Disclosures: SINUS-24 was funded by Regeneron and Sanofi, the companies that market dupilumab (Dupixent). Dr. Han has been an adviser to Regeneron and Sanofi.
Han JK et al. AAAAI,.
Must Reads in Asthma
Antibiotic Therapy in Patients with Asthma, JAMA Intern Med; ePub 2019 Jan 28; Stefan, et al
Asthma Toolkit Improves Measures of Asthma Care, J Am Board Fam Med; 2019 Jan; Colborn, et al
FDA Approves Fasenra for Severe Eosinophilic Asthma, AstraZeneca news release; 2017 Nov 14